CNBX PHARMACEUTICALS INC.: 10-K filed 2022-11-30
What CNBX PHARMACEUTICALS INC. reported in its annual report filed 2022-11-30 (fiscal FY 2022): 28 published measures, 58 facts as tagged in accession 0001683168-22-008095.
This filing
- Form
- 10-K (annual report)
- Filed
- 2022-11-30
- Fiscal period
- fiscal FY 2022
- Accession
- 0001683168-22-008095 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CNBX PHARMACEUTICALS INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-08-31 | 811,166 | USD | |
| At 2021-08-31 | 3,078,961 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-08-31 | -1,632,311 | USD | |
| At 2021-08-31 | 1,805,915 | USD | |
| At 2020-08-31 | 1,764,524 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-08-31 | 117,515 | USD | |
| At 2021-08-31 | 1,386,472 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | -3,723,250 | USD | 365 |
| 2020-09-01 to 2021-08-31 | -3,194,447 | USD | 365 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | -1,679,192 | USD | 365 |
| 2020-09-01 to 2021-08-31 | -2,492,913 | USD | 365 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | 389,858 | USD | 365 |
| 2020-09-01 to 2021-08-31 | 2,456,750 | USD | 365 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | 25,229 | USD | 365 |
| 2020-09-01 to 2021-08-31 | 645,025 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-08-31 | -20,548,968 | USD | |
| At 2021-08-31 | -16,825,718 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | 1,222,641 | shares | 365 |
| 2020-09-01 to 2021-08-31 | 138,519,509 | shares | 365 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | 1,222,641 | shares | 365 |
| 2020-09-01 to 2021-08-31 | 138,519,509 | shares | 365 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | -3.59 | USD/shares | 365 |
| 2020-09-01 to 2021-08-31 | -0.02 | USD/shares | 365 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | -3.59 | USD/shares | 365 |
| 2020-09-01 to 2021-08-31 | -0.02 | USD/shares | 365 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-08-31 | 436,792 | USD | |
| At 2021-08-31 | 642,896 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | 728,869 | USD | 365 |
| 2020-09-01 to 2021-08-31 | 0 | USD | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | -2,953,970 | USD | 365 |
| 2020-09-01 to 2021-08-31 | -2,600,177 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-08-31 | 198,287 | USD | |
| At 2021-08-31 | 1,590,847 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-08-31 | 2,443,475 | USD | |
| At 2021-08-31 | 1,273,046 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | 2,953,970 | USD | 365 |
| 2020-09-01 to 2021-08-31 | 2,600,177 | USD | 365 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | 1,183,281 | USD | 365 |
| 2020-09-01 to 2021-08-31 | 1,771,533 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-08-31 | 1,257,927 | shares | |
| At 2021-08-31 | 148,661,247 | shares |
Cash including restricted cash
Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-08-31 | 117,515 | USD | |
| At 2021-08-31 | 1,386,473 | USD | |
| At 2020-08-31 | 777,611 | USD |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-08-31 | 18,031,869 | USD | |
| At 2021-08-31 | 17,063,363 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-08-31 | -2,574,846 | USD | |
| At 2021-08-31 | -1,905,715 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-08-31 | 0 | USD | |
| At 2021-08-31 | 0 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | -4,392,381 | USD | 365 |
| 2020-09-01 to 2021-08-31 | -2,325,751 | USD | 365 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | 1,770,689 | USD | 365 |
| 2020-09-01 to 2021-08-31 | 828,644 | USD | 365 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | 198,527 | USD | 365 |
| 2020-09-01 to 2021-08-31 | 220,926 | USD | 365 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-09-01 to 2022-08-31 | 769,280 | USD | 365 |
| 2020-09-01 to 2021-08-31 | 594,270 | USD | 365 |
Inspect the source
- Entity
- CNBX PHARMACEUTICALS INC. / CIK 0001343009
- Captured
- SEC response SHA-256
915b78bb9f3d1ecdaff39577a9e5db4b6d0b32a87b795bd1dd92ab6d7b14ac19
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001343009.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))